HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MIRM
Mirum Pharmaceuticals, Inc.
MIRM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MIRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Weak |
MIRM's revenue is currently healthy, but its profitability, cash flow and balance sheet are weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MIRM PE Valuation
MIRM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over MIRM on the outlook, with more favorable profitability expectations.
MIRM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect MIRM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MIRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.46 | -$14.60 |
| Q2 2026 | -$14.54 | -$13.33 |
| Q1 2026 | -$13.60 | -$11.99 |
| Q4 2025 | -$0.47 | +$1.38 |
| Q3 2025 | -$0.86 | +$1.19 |
| Q2 2025 | -$1.21 | +$1.11 |
| Q1 2025 | -$1.61 | +$2.13 |
| Q4 2024 | -$1.85 | +$2.15 |
MIRM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MIRM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MIRM on profitability, with a higher operating margin.
MIRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $185.7M | +40% |
| Q2 2026 | $176.2M | +38% |
| Q1 2026 | $159.9M | +43% |
| Q4 2025 | $148.9M | +50% |
| Q3 2025 | $133M | +47% |
| Q2 2025 | $127.8M | +64% |
| Q1 2025 | $111.6M | +61% |
| Q4 2024 | $99.4M | +43% |
MIRM's revenue has grown year over year every quarter since mid-2022: $186M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -32% | -34 points |
| Q2 2026 | -24% | -20 points |
| Q1 2026 | -494% | -480 points |
| Q4 2025 | -3.1% | +21 points |
| Q3 2025 | 2% | +16 points |
| Q2 2025 | -3.9% | +27 points |
| Q1 2025 | -14% | +25 points |
| Q4 2024 | -24% | +23 points |
MIRM's operating margin was −32% last quarter, down 34 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MIRM on cash generation, producing positive trailing cash flow while its opponent burns cash.
MIRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | -114% |
| Q2 2026 | -$44.3M | -472% |
| Q1 2026 | -$229.4M | -$227.4M |
| Q4 2025 | $5.5M | +$10.6M |
| Q3 2025 | $39.5M | +938% |
| Q2 2025 | $11.9M | +$16.5M |
| Q1 2025 | -$2M | -113% |
| Q4 2024 | -$5.1M | +$11.5M |
MIRM has burned cash in most quarters: −$274M over the past year, against $44M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MIRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MIRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.2% | +2.7M shares |
| 1 year | +16% | +9.1M shares |
| 3 years | +61% | +25M shares |
| 5 years | +117% | +35.7M shares |
| Available history | +167% | +41.3M shares |
MIRM has 66M diluted shares, up 16% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over MIRM on leverage, with a lower net debt burden relative to earnings.
MIRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 6.2x | High |
MIRM's net debt is about 6.2 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MIRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.3 | Neutral |
| Stochastic | 43.7 | Neutral |
MIRM's weekly RSI is 49 (neutral) and its Stochastic is 44 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MIRM PE vs Healthcare Sector
MIRM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MIRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $86.4 | 8% above |
| 20 week MA | $98.1 | 4.9% below |
| 50 week MA | $95.4 | 2.2% below |
| 100 week MA | $75.2 | 24% above |
| 200 week MA | $52.8 | 77% above |
MIRM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MIRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.9 | $18.3 | -30% |
| 2021 | $18.3 | $15.6 | -15% |
| 2022 | $15.6 | $18.2 | +17% |
| 2023 | $18.2 | $29.5 | +62% |
| 2024 | $29.5 | $41.6 | +41% |
| 2025 | $41.6 | $79.3 | +91% |
| 2026 YTD | $79.3 | $93.3 | +18% |
MIRM has the edge over HIMS on returns for 2026, with the stronger performance.